- Duration: 3 Days
The Boston AF Symposium was initiated in 1995 in response to the growing epidemic of atrial fibrillation and to highlight the early work being done on the feasibility of catheter ablation as a potential treatment option of the future. In sixteen years, this meeting has evolved into a major scientific forum at which health care professionals have a unique opportunity to learn about all aspects of atrial fibrillation research and therapeutics directly from many of the most innovative investigators in the field. This intensive and highly focused three-day symposium brings together leading medical scientists from all over the world to teach, discuss and debate in a highly interactive environment the most current advances in the field of atrial fibrillation.
The primary objective of the meeting is to provide attendees with an in-depth view of the current state of the art in the field of atrial fibrillation in a scholarly and collegial atmosphere. In addition to its world-class international faculty, the meeting employs some of the most advanced teaching tools including satellite and pre-recorded case demonstrations and audience response systems. Each year, we strive for a fresh and innovative approach to communicating the most up-to-date basic, translational and clinical science as they evolve toward a more complete understanding of the pathophysiology of atrial fibrillation with the primary goal of developing safer and more effective strategies for the treatment of this common arrhythmia.
Seaport Hotel World Trade Center
Boston , MA USA
Jeremy N. Ruskin, MD
Moussa Mansour, MD
Vivek Reddy, MD
David Keane, MD, PhD
This three-day symposium is designed to meet the following two objectives:
- Provide a current review of new information on the basic and clinical science and pathophysiology of atrial fibrillation and atrial fibrillation-related stroke.
- Provide a detailed presentation of the most recent developments in the diagnosis and treatment of atrial fibrillation and prevention of AF-related stroke and other sequelae, with an emphasis on current and evolving pharmacologic and nonpharmacological therapies and enabling new technologies in the field of cardiac electrophysiology.